Corporate StrategyNovo Nordisk Exits Cell Therapy, Hands Parkinson's Assets to AI Startup as Pharma Rewires R&DSalvado•Jun 19, 2026
Pharmaceutical StrategyNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal UnitSalvado•Jun 5, 2026
Corporate PartnershipsNVIDIA's BioNeMo Becomes Pharma's Shared AI Backbone as Platform Race With Specialized Rivals Heats UpSalvado•May 27, 2026
Strategic PartnershipsNVIDIA Locks In Dual Pharma Deals With Eli Lilly and Thermo Fisher, Making BioNeMo Drug Discovery's Core AI LayerSalvado•May 1, 2026
Corporate StrategyNVIDIA's BioNeMo Platform Secures Eli Lilly and Thermo Fisher as Enterprise AI Revenue ExpandsSalvado•Apr 21, 2026
Corporate Technology InvestmentNVIDIA Partners with Eli Lilly, Thermo Fisher to Anchor AI Drug Discovery InfrastructureSalvado•Apr 17, 2026
Corporate StrategyNVIDIA BioNeMo Platform Secures Partnerships With Lilly, Thermo Fisher in Drug Discovery AI PushSalvado•Apr 14, 2026
Corporate FinanceNVIDIA's BioNeMo Platform Secures Eli Lilly Partnership as Biotech AI Competition IntensifiesSalvado•Apr 12, 2026
Corporate StrategyNVIDIA Locks In Pharma Giants Lilly and Thermo Fisher as Biotech AI Race AcceleratesSalvado•Apr 11, 2026
Corporate StrategyNVIDIA Secures Eli Lilly, Thermo Fisher for BioNeMo Platform in Pharma AI PushSalvado•Apr 11, 2026
Corporate StrategyNVIDIA Partners with Eli Lilly, Thermo Fisher to Drive BioNeMo AI Drug Discovery PlatformSalvado•Apr 10, 2026
Corporate FinanceNVIDIA BioNeMo Platform Powers AI Drug Discovery Push by Eli Lilly, Thermo FisherSalvado•Apr 10, 2026
Biotech InvestmentNVIDIA BioNeMo Platform Secures Lilly and Thermo Fisher as AI Drug Discovery Partnerships AccelerateSalvado•Apr 9, 2026
Corporate Technology InvestmentNVIDIA BioNeMo Platform Gains Eli Lilly, Thermo Fisher as Pharma Firms Accelerate AI Infrastructure SpendSalvado•Apr 9, 2026
Corporate StrategyNVIDIA Secures Lilly and Thermo Fisher as BioNeMo Platform Anchors AI-Driven Drug Discovery EcosystemSalvado•Mar 26, 2026
Corporate StrategyNVIDIA BioNeMo Platform Secures Eli Lilly and Thermo Fisher as Strategic Partners in Drug Discovery PushSalvado•Mar 23, 2026
Corporate PartnershipsNVIDIA BioNeMo Wins Thermo Fisher, Eli Lilly as AI Drug Discovery PartnersSalvado•Mar 22, 2026
Corporate FinanceNVIDIA's BioNeMo Bets Signal a Tectonic Shift in Pharma R&D Capital AllocationViaNews Editorial Team (Finance)•Feb 18, 2026
Biotech InvestmentNVIDIA's BioNeMo Partnerships With Eli Lilly and Thermo Fisher Signal Institutional Capital Shift Into AI Drug DiscoveryViaNews Editorial Team (Finance)•Feb 18, 2026
